Cholesterol Drug

Source: au.rd.yahoo.com --- 49 days ago
NEW YORK (Reuters Health) - The number of U.S. adults on Cholesterol-lowering medication could rise by one-quarter to one-half if doctors were to routinely scan adults' arteries for plaque buildup, a study suggests. ...

Source: www.iht.com --- 4 days ago
Schering-Plough and Merck's Cholesterol Drug Vytorin doesn't lower the risk of major heart valve problems and need for related surgical procedures, according to a large-scale study. ...

Source: heartdisease.about.com --- 15 days ago
The American Academy of Pediatrics (AAP) released a controversial set of recommendations last week regarding the treatment of lipid abnormalities in children. The new recommendations, apparently stimulated by growing... ...

Source: www.nytimes.com --- 4 days ago
Merck and Schering-Plough said new test results show that their heart Drug Vytorin failed to meet its main goal of improving cardiovascular outcomes. ...

Source: www.moreover.com --- 16 hours ago
The weakness and muscle pain experienced by some people who take the Cholesterol-lowering drugs called statins is for the first time being linked to a common gene variation, researchers report in a study being released Thursday. ...

Source: www.moreover.com --- 4 days ago
In the latest disappointment over Cholesterol pill Vytorin, a major European study in patients with heart valve disease found the Drug did not prevent worsening of the disease or lower the need for valve surgery. ...

Source: www.moreover.com --- 4 days ago
TRENTON, N.J. (AP) _ In the latest disappointment for Cholesterol pill Vytorin, a major European study in patients with heart valve disease found the Drug didn't prevent worsening of the disease or lower the need for valve surgery, sending its makers' ...

Source: www.moreover.com --- 49 days ago
NEW YORK (Reuters Health) - The number of U.S. adults on Cholesterol-lowering medication could rise by one-quarter to one-half if doctors were to routinely scan adults' arteries for plaque buildup, a study suggests. ...

Source: www.boston.com --- 31 days ago
Genzyme Corp. and Isis Pharmaceuticals Inc. said today that they finalized their agreement to give Genzyme exclusive rights to mipomersen, a Cholesterol Drug candidate discovered and developed by Isis. Under original terms of the deal, first announced in January, Genzyme of Cambridge bought five million Isis shares for $150 million and agreed to pay Isis a $175 million upfront license fee. The companies now say California-based Isis will contribute up to $50 million in additional development funding for mipomersen, bringing the company's funding commitment up to $125 million. After that, Isis and Genzyme will share development costs equally. In exchange for the additional contribution, Isis may receive $75 million in milestone payments early. Mipomersen is currently in late-stage trials to treat patients with homozygous familial hypercholesterolemia, a severe form of high Cholesterol. The companies expect to apply with the Food and Drug Administration in the second half of 2010 for approval, and will approach regulatory authorities in Europe. The companies said other financial terms are unchanged under the final agreement. Isis is eligible to receive up to $750 million in commercial milestone payments and up to $825 million in development and regulatory milestone fees. Genzyme and Isis will share mipomersen profits on a sliding scale. The split will be 50/50 when annual revenue reaches $2 billion. As part of the relationship, Genzyme ...

Source: www.boston.com --- 3 days ago
NEW YORK - Merck & Co. and Schering-Plough Corp. fell in New York trading after their Cholesterol Drug Vytorin failed in a study to prevent complications from heart-valve disease and was linked to a higher rate of cancer. ...

Source: latimesblogs.latimes.com --- 3 days ago
Vytorin, the combination Drug prescribed to lower Cholesterol, sustained another blow today, when the author of a major clinical trial announced that the medication had failed to drive down hospitalization and death due to heart failure in patients with narrowing of the aortic valve. In the process, researchers in Norway detected a significant blip in cancers in the 1,800 subjects they followed. This is the second time in less than six months that Vytorin, the widely-prescribed -- and heavily advertised -- combination of the blockbuster drugs simvastatin (better known by its commercial name Zocor) and ezetimibe (known as Zetia) has fallen short on the goal of preventing heart attacks. In March, a study known as the ENHANCE trial found that Vytorin fared no better than a placebo at reducing plaque buildup on the walls of patients' arteries. Today's findings suggested something more ominous: the incidence of cancer -- and of dying of cancer -- was significantly higher in the patients taking Vytorin. Altogether, 67 patients on placebo developed cancer during the trial. Among subjects on Vytorin, 102 developed cancers of various kinds. Researchers involved in Vytorin trials believe the surprising blip in cancer rates among those on the Cholesterol-lowering Drug may be a statistical blip, but promised to continue to explore any link between the two. Vytorin did lower the risk of ischemic events -- heart attacks or strokes caused by blockage ...

Source: www.iht.com --- 17 days ago
Proponents say there is growing evidence that the first signs of heart disease show up in childhood, and with 30 percent of children in the United States overweight or obese, many doctors fear a rash of early heart attacks and diabetes is on the horizon as these children grow up. ...

Source: www.npr.org --- 3 days ago
A study released Monday of adults with heart disease found no evidence that using Cholesterol drugs Vytorin and Zetia lowers heart-valve disease. The study's results sent shares of the companies that make the drugs tumbling. ...

Source: www.medicinenet.com --- 8 days ago
Title: Cholesterol Drug Controversy Continues Category: Health News Created: 3/31/2008 2:00:00 AM Last Editorial Review: 3/31/2008 ...

Source: www.medicinenet.com --- 8 days ago
Title: Cholesterol Drug Zetia Doesn't Cut Heart Attack Risk: Study Category: Health News Created: 1/15/2008 2:00:00 AM Last Editorial Review: 1/15/2008 ...

Source: www.moreover.com --- 22 days ago
Morningstar.com Jul 3 2008 7:22PM GMT ...

Source: www.moreover.com --- 9 days ago
FierceBiotech Jul 15 2008 10:04PM GMT ...

Source: www.moreover.com --- 12 days ago
PSL Group Jul 12 2008 5:43AM GMT ...

Source: www.moreover.com --- 35 days ago
Lloyd's Jun 20 2008 7:37PM GMT ...

Source: www.naturalnews.com --- 17 days ago
(NaturalNews) In the latest example of absurd disease mongering to receive widespread media attention, the American Academy of Pediatrics Committee has announced that infants as young as two years old need to be screened for high Cholesterol, and children as young as eight years old should be put on prescription statin drugs. This absurd advice is being offered even though statin drugs have never been tested on children, nor approved by the FDA for use on children. The point of all this? To sell more high-profit prescription drugs, of course, to yet another group of victims being targeted for medication by Big Pharma. This is called "market expansion," and it's the only way Drug companies can continue to grow their profits and keep shareholders happy. As Drug companies continue to expand their profits and influence over the now-utterly-corrupt medical industry, they are also expanding their customer base by continuing to push medications for increasingly younger demographic groups. Not content to Drug more than half the adults in western nations, Big Pharma now sees children as its next area of market growth, in much the same way that soda companies once sought to persuade parents to feed their babies soda pop as a way to instill the desire for sugary beverages at a very young age. The conventional medical profession -- which has long since sold its soul to the Drug companies and now functions as little more than an elaborate pharmaceut ...